A Double-Blind, Randomised, Placebo-Controlled Trial Confirming the Efficacy of Intranasal Fentanyl Titrated to 50, 100 or 200 microg With an Open Long-Term Safety Follow-up in Cancer Patients With Breakthrough Pain.
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2012 Planned number of patients changed from 100 to 200.
- 02 Feb 2010 Actual end date changed from Jan 2008 to Mar 2008 as reported by ClinicalTrials.gov.
- 28 Jul 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History